They all combine a strong anti-angiogenic component, via direct inhibition of the vascular endothelial growth factor receptors (VEGFRs), with the inhibition of key oncogenic RTKs implicated in paediatric and AYA sarcoma, including the platelet-derived growth factor receptors (PDGFRs), c-KIT, fibroblast growth factor receptors (FGFRs), RET, and/or MET. This evidence concerns the gene MET and sarcoma.